Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in tr

Alnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigati

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics fo

Analysts remain bullish about Alnylam despite its steep sell-off. The competitive landscape for Alny

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on

Arizona State Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: A

Concurrent Investment Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (N

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Trans

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:AL

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline cata

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have been given a consensus

[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, to

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its invest

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer and Check, LLP Encourages Alnylam Pharmaceutica

RADNOR, Pa., Aug. 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati

RADNOR, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a

If you purchased or acquired stock in Alnylam and would like to discuss your legal rights, contact B

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDA

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are gree

LOS ANGELES, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national

BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) wi

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a B

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALN

Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperfor

Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowe

Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform a

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-W

Oppenheimer analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outpe

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lo

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe

Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance

Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular

US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectation

Alnylam Pharmaceuticals (NASDAQ:ALNY) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.84 per share which beat the